GO
Loading...

Roche Holding AG

More

  • Cramer: Investing in Future of Cancer Drugs Thursday, 4 Apr 2013 | 6:28 PM ET

    At least three companies are on the cutting edge of new treatments for perhaps the most feared disease known to mankind.

  • New Bird Flu Cases Rise in China, Three Deaths Wednesday, 3 Apr 2013 | 8:21 PM ET

    China has found two more cases of a new strain of bird flu and one of the victims has died, bringing to nine the number of confirmed human infections from the previously unknown flu type.

  • India's top court has dealt a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales.

  • Cramer: Already High, This Stock Trades Higher Wednesday, 27 Mar 2013 | 6:14 PM ET

    Share price may already seem high but Jim Cramer thinks it deserves to be even higher.

  • Facebook Taps Genentech Veteran for Board Thursday, 7 Mar 2013 | 7:06 AM ET
    A Nasdaq television reporter is seen inside the Nasdaq studios as the Facebook logo is displayed on a ticker board.

    Facebook appointed a former Genentech executive to its board of directors, the social networking company's latest move to expand its boardroom following its initial public offering last May.

  • Swiss Back Strict Executive Pay Curbs Sunday, 3 Mar 2013 | 5:38 PM ET

    Swiss citizens voted on Sunday to impose some of the world's strictest controls on executive pay, forcing public companies to give shareholders a binding vote on compensation, result projections showed.

  • European Shares Post Worst Daily Fall for a Month Wednesday, 30 Jan 2013 | 10:11 AM ET

    European shares suffered their biggest daily drop this month after gloomy earnings and weak U.S. economic data hit sentiment on Wednesday and left some positioning for further falls in the near-term.

  • Futures Lose Gains on GDP Surprise Wednesday, 30 Jan 2013 | 7:36 AM ET

    U.S. stock index futures pointed to a slightly higher open on Wednesday, with eyes on the Federal Reserve’s first policy statement of 2013.

  • Roche CEO: We See a Stable Headcount in Europe     Wednesday, 30 Jan 2013 | 2:00 AM ET

    Severin Schwan, CEO of Roche, tells CNBC that 2012 was a very good year for Roche with the company outgrowing their markets in both Pharma and Diagnostics by five and four percent.

  • 13 Biotech Stock Predictions for 2013 Wednesday, 2 Jan 2013 | 7:55 AM ET

    TheStreet.com offers up 13 biotech predictions for 2013.

  • Big Pharma Bets on Obesity Drug Binge Thursday, 27 Dec 2012 | 2:18 AM ET

    As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.

  • Early Movers: NYX, ICE, CAG & More Thursday, 20 Dec 2012 | 7:46 AM ET

    Some of the names on the move ahead of the open.

  • Roche CEO: We Will Achieve Full Year Target     Tuesday, 16 Oct 2012 | 3:30 AM ET

    Severin Schwan, CEO of Roche, tells CNBC, that the company is on track to achieve its full year target, but they are sticking to the guidance that they gave at the beginning of the year.

  • Roche: Best Company in European Sector?     Tuesday, 16 Oct 2012 | 3:15 AM ET

    Andrew Weiss, head of Life Science at Vontobel, tells CNBC, Roche is the best pick in the European sector, the company with the least amount of problems and innovation within the company.

  • Illumina Plays Offense & Final Trade     Tuesday, 17 Apr 2012 | 12:55 PM ET

    CNBC's Kayla Tausche reports on Illumina playing offense against Roche's hostile takeover bid, and the FMHR crew share their final trades of the hour.

  • Faber Report: Illumina     Tuesday, 17 Apr 2012 | 9:42 AM ET

    CNBC's David Faber reports the latest details on Illumina's recommendation to shareholders to reject Roche's takeover offer.

  • Roche: Beware of Fake Avastin     Wednesday, 15 Feb 2012 | 11:10 AM ET

    A serious warning is out to patients, doctors and hospitals telling everyone to beware of a fake version of Roche's cancer-fighting drug Avastin. Insight with Scott Gottlieb, MD.

  • Considering Illumina just adopted a poison pill defense strategy, you might think a deal with Roche is out of the question. But Karen Finerman says it's not.

  • Finerman's Fine Print: Illumina Rejects Roche     Wednesday, 8 Feb 2012 | 5:29 PM ET

    Karen Finerman, Metropolitan Capital Advisors, and Fast Money trader, provides insight on what's next for Illumina, on the heels its recent rejection of Roche's offer.

  • Roche CEO on Illumina Deal     Friday, 3 Feb 2012 | 11:25 AM ET

    Insight on the value that will be created by a transaction with Illumina, with Severin Schwan, Roche CEO, who discusses Roche's offer for Illumina.